Form 4: Edwards Lifesciences Insider Sells Shares

Daniel J. Lippis, a Corporate Vice President at Edwards Lifesciences Corp, reported a transaction involving the withholding of shares to cover tax obligations.

Summary

• Daniel J. Lippis, identified as a Corporate Vice President (CVP) and responsible for TAVR (Transcatheter Aortic Valve Replacement) at Edwards Lifesciences Corp, has reported a transaction.
• The transaction, dated July 7, 2026, involved the withholding of 377 shares of common stock by the Issuer.
• These shares were withheld to satisfy tax withholding obligations related to the vesting of securities.
• The price associated with this transaction was $95.18 per share.
• Following this transaction, Mr. Lippis beneficially owns 40,033.9103 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine tax-related share withholding by an executive and does not signal a change in investment sentiment or company performance.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive shareholdings and activities. This specific filing details a common practice of share withholding for tax purposes upon vesting, which is not typically indicative of a change in management's outlook on the company's stock.

Stakeholder Impact

• Shareholders: The transaction is a routine tax event for the executive and is not expected to have a direct impact on the company's share price or overall market performance.
• Employees: This filing pertains to executive compensation and tax obligations, with no direct impact on general employee operations.
• Management: Confirms standard executive compensation and tax management practices.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Transaction, Stock Withholding, Tax Obligations, Beneficial Ownership, TAVR